LatestNews

OMass Therapeutics Announces £14 Million Series A Financing to Build a Pipeline of Proprietary Medicines
November 21, 2018

– Developing novel medicines using structural mass spectrometry – Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biopharmaceutical company using…

Read More
OMass Therapeutics is Expanding its Team
November 20, 2018

Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding…

Read More
OMass Technologies Announces Publication Demonstrating the Impact of Lipid interactions on GPCR Signalling in Nature
July 11, 2018

Oxford, 11 July 2018 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today announced…

Read More
OMass Technologies secures INNOVATE UK funding in collaboration with the University of Oxford
June 15, 2018

Oxford, 15 June 2017 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today announced…

Read More
Publications

Selected abstracts and publications from OMass and collaborators showcasing our cutting-edge science.

Read More
Careers

Find out more about life at OMass and current vacancies in our careers section

Read More